ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting

Hørsholm, Denmark, 24 June 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces that the company presented a poster on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens, at the European Society for Animal Cell Technology (ESACT) bi-annual meeting, taking place 23-26 June 2024, in Edinburgh, Scotland.

The presentation poster titled “Use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens” showcases novel glyco-modified versions of the ExpreS2 platform (GlycoX-S2™) enabling enhanced immunogenicity of vaccines. It concludes, that:

• Modified recombinant antigens with high-mannose or xylosylated N-glycans produced significantly higher antibody titers in immunized mice compared to antigens with S2 wildtype N-glycans.

• Although presenting antigens on virus-like particles substantially enhances immunogenicity, a similar effect can be achieved through glycomodification of the soluble antigen.

• Both approaches resulted in high antibody titers and their neutralizing capabilities were shown in the virus neutralisation assay for high-mannose antigen.

A copy of the poster can be found at the company webpage www.expres2ionbio.com/events-list/.

For further information about ExpreS2ion, please go to our webpage www.expreS2ionbio.com, or contact us at info@expreS2ionbio.com.

About ExpreS2ion

ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.

Tags: